Myocardial remodeling and fibroblast growth factor in patients with resistant hypertension

Litvinova M. S.[1,2], Khaisheva L. A.[1], Shlyk S. V.[1]

Aim. To study the prevalence and severity of left ventricular hypertrophy (LVH), its relationship with fibroblast growth factor (FGF23) in patients with resistant hypertension (RH) depending on the effectiveness of multiagent antihypertensive therapy.

Material and methods. The study included 92 patients diagnosed with RH. All patients underwent 24-hour ambulatory blood pressure monitoring (ABPM), echocardiography, general laboratory tests, and the serum FGF23 level was determined.

Results. According to ABPM results, patients were divided into following groups: 1st — controlled RH (n=44) and 2nd — uncontrolled (n=48) RH. The groups were comparable in sex, age, main clinical and anthropometric parameters. In group 2, the main parameters of ABPM were higher. There were no differences in general laboratory tests, In the group of uncontrolled RH, the level of FGF23 was higher — 11,7 [8,5; 15,4] pmol/ml vs 9,2 [7,1; 11,6] pmol/ml in the 1st group (p=0,0036). According to echocardiography, a comparable violation of left ventricular (LV) diastolic function, an increase in left atrial size, LV mass (LVM) and LVM index were found. In patients of the 2nd group, large values of interventricular septal thickness were revealed — 1,3 [1,2; 1,4] cm vs 1,2 [1,1; 1,3] cm in the 1st group (p=0, 0043) and relative LV wall thickness (LWWT) — 0,50 [0,48; 0,53] vs, 0,45 [0,43; 0,50] in the 1st group (p<0,0001). In the 1st and 2nd groups, concentric LVH was more common (18 (41%) patients in the 1st and 26 (54,1%) in the 2nd (p=0,044) groups) than eccentric LVH (15 (34,1%) and 13 (27,1%) patients in the 1st and 2nd groups, respectively). Correlation analysis revealed a positive relationship between pulse pressure and HTN duration (r=48, p=0,02) and FGF23 level (r=0,62, p=0,004). The LVM index was positively associated with the diastolic pressure-time index (BP) (r=51, p=0,02). A positive correlation was found between relative LWWT and pulse pressure (r=0,64, p=0,02) and a negative relationship with the duration of regular antihypertensive therapy (r=47, p=0,04). A strong relationship was found between LVEF and FGF23 levels (r=0,75, p=0,005).

Conclusion. For patients with uncontrolled resistant hypertension, an increase in pulse pressure and myocardial remodeling in the form of concentric hypertrophy are more characteristic. FGF23 is significantly higher in uncontrolled RH and is positively associated with pulse pressure and relative LWWT.

Keywords: resistant hypertension, left ventricular myocardial hypertrophy, fibroblast growth factor.

Relationships and Activities: none.

[1]Rostov State Medical University, Rostov-on-Don; [2]Clinical and Diagnostic Center "Health", Rostov-on-Don, Russia.

Litvinova M. S.* ORCID: 0000-0003-2904-0914, Khaisheva L. A. ORCID: 0000-0002-2419-4319, Shlyk S. V. ORCID: 0000-0003-3070-8424.

*Corresponding author:
litvinova.m.803@mail.ru

Hypertension (HTN) is still the leading cause of cardiovascular deaths [1]. A special place is occupied by resistant hypertension, in which blood pressure (BP) remains >140/90 mm Hg, despite the simultaneous use of 3 antihypertensive drugs, including a renin-angiotensin-aldosterone system (RAAS) inhibitor, a calcium channel antagonist and a diuretic in maximum tolerated doses [2].

Key messages

- Resistant hypertension, even with adequate blood pressure (BP) control, is associated with more pronounced target organ damage, including left ventricular (LV) myocardial hypertrophy.
- In addition to the generally accepted factors leading to LV myocardial hypertrophy, direct mediators of myocardial hypertrophy, in particular fibroblast growth factor 23 (FGF23), have been identified.
- In patients with resistant hypertension, FGF23 is associated with poor BP control, higher pulse pressure, and unfavorable LV remodeling.

Resistant hypertension is associated with more pronounced target organ damage, including left ventricular hypertrophy (LVH) [3]. According to a meta-analysis of 11 studies involving 3325 patients with resistant HTN, the prevalence of LVH varies from 55 to 75% [4], while in the population of all hypertensive patients, the prevalence of LVH ranges from 36 to 41% (in the general population ~15-20%) [5]. It has been repeatedly demonstrated that LVH is an independent predictor of cardiovascular events (CVEs) in individuals with HTN [6] and in the general population [7]. Currently, the main causes leading to the development and progression of LVH in hypertensive patients are recognized as poor BP control, age, sex, obesity, hyperactivity of the sympathetic nervous system and RAAS, low physical activity, and concomitant heart diseases [8].

In addition, the search for new pathogenetic ways for LVH development continues in order to develop modern therapeutic approaches aimed at reducing cardiovascular morbidity and mortality. In recent years, special attention has been drawn to fibroblast growth factor-23 (FGF23), a phosphaturic protein involved in the regulation of mineral metabolism, vascular calcification and being an independent risk factor for CVEs. The level of FGF23 increases with the progression of chronic kidney disease, reaching maximum values in individuals with end-stage renal disease [9]. A less pronounced increase in the concentration of FGF23 is observed with age, even in individuals with preserved or slightly reduced renal function [10]. According to experimental data, FGF23 is a direct mediator of LVH development not only in a cohort of patients with chronic kidney disease [11], but also in the general population [10]. An association between the progression of LVH and the serum level of FGF23 was also demonstrated in a model of hypertensive rats [12]. FGF23 causes pathological hypertrophy of isolated cardiomyocytes through binding to the FGFR4 receptor and activation of the calcineurin-NFAT pathway [13]. In addition to triggering prohypertrophic gene programs, FGF23 can induce LVH by increasing the expression of profibrotic factors and inflammatory cytokines in cardiomyocytes [14]. FGF23 is able to influence the renal expression of angiotensin-converting enzyme-2, thereby increasing the activity of the RAAS [15]. At the same time, in most published studies, the severity of myocardial hypertrophy depended on the plasma FGF23 concentration [10-14]. However, in some studies, the degree of left ventricular (LV) remodeling was associated with the duration of FGF23 exposure to the myocardium, regardless of its level [16]. It is well known that modern antihypertensive therapy can affect the regression of LVH and the reduction of cardiovascular events and mortality, regardless of the achievement of the target blood pressure level, including in persons with resistant HTN [17].

We hypothesized that in this cohort of patients, myocardial remodeling, in addition to generally recognized factors such as blood pressure levels, may be influenced by other factors, for example, those responsible for calcification and vascular stiffness. In the available literature, there are no studies on the relationship between LVH and FGF23 in patients with resistant HTN. In this regard, the aim of our work was to study the prevalence and severity of LVH and its relationship with fibroblast growth factor in patients with resistant HTN, depending on the effectiveness of antihypertensive therapy.

Material and methods

An open-label cross-sectional comparative study was carried out on the basis of the Rostov State Medical University and the "Health" Clinical and Diagnostic Center in Rostov-on-Don in the period from 2017 to 2021. The study protocol was approved by the local ethics committee of Rostov State Medical University. At the screening stage, a retrospective analysis of 4874 outpatient records of patients aged 18 to 70 years with a diagnosis of essential (primary) hypertension was performed, as a result of which a group of patients requiring 3 or more antihypertensive drugs was identified. Excluding patients with symptomatic HTN, patients with a decrease in glomerular filtration rate (GFR) estimated by the CKD-EPI

Table 1

Clinical and demographic characteristics of patients (Me [25%; 75%])

Parameters	Controlled HTN (n=44)	Uncontrolled HTN (n=48)	p
Age, years	61,0 [56,0; 66,0]	62,0 [58,0; 67,0]	0,229
Sex (male, %)	13 (29,5)	15 (31,3)	0,172
Positive family history for CVD, %	22 [50,0]	25 [51,0]	0,443
HTN duration, years	14,0 [9,0; 17,0]	15,0 [8,0; 18,0]	0,213
Duration of therapy, years	7,0 [4,0; 8,0]	5,0 [4,0; 7,0]	0,034
Number of drugs taken	4,4 [4,0; 4,6]	4,4 [4,1; 4,6]	0,673
BMI, kg/m^2	31,8 [30,0; 35,8]	29,9 [27,2; 34,3]	0,197
WC, cm	90,0 [85,0; 98,0]	93,0 [87,0; 104,0]	0,256

Abbreviations: HTN — hypertension, BMI — body mass index, WC — waist circumference.

Table 2

Assessment of target organ damage in patients with resistant HTN (Me [25%; 75%])

Parameters	Controlled HTN (n=44)	Uncontrolled HTN (n=48)	p
GFR according to the CKD-EPI equation, ml/min/1,73 m^2	82,0 [74,0; 87,0]	80,0 [71,0; 86,0]	0,112
MAU, mg/ml	9,0 [6,8; 10,7]	10,0 [6,9; 11,5]	0,238
LVMI, g/m^2	133,0 [115,0; 145,0]	134,0 [121,0; 150,0]	0,591
IMT	1,0 [1,0; 1,0]	1,0 [1,0; 1,0]	0,443

Abbreviations: HTN — hypertension, LVMI — left ventricular mass index, MAU — microalbuminuria, GFR — glomerular filtration rate, IMT — intima-media thickness.

<60 ml/min/1,73 m^2 and microalbuminuria (MAU) >30 mg/day, persons with severe endocrine disorders (diabetes, thyroid dysfunction, parathyroid dysfunction, vitamin D deficiency), coronary artery disease, hemodynamically significant atherosclerosis of peripheral arteries, class III-IV heart failure, arrhythmias, as well as persons with concomitant therapy that can affect BP levels (oral contraceptives, sympathomimetics, non-steroidal anti-inflammatory drugs) and FGF23 levels (vitamin D, calcimimetics, phosphate binders), 151 people with probable resistant HTN were selected, who then underwent pharmacotherapy optimization for at least 6 months. Treatment adherence was assessed using the Brief Medication Questionnaire (BMQ) and monitoring the number of pills taken. The effectiveness of therapy was monitored by home BP measurement. As a result, the study included 92 patients diagnosed with resistant HTN, established on the basis of the Russian Society of Cardiology (2020) guidelines [2], who did not reach the target BP level, despite the simultaneous use of 3 antihypertensive drugs of different classes, including a RAAS blocker, a calcium channel blocker, and diuretic at maximum tolerated doses or achieved target BP while taking ⩾4 antihypertensive drugs.

In all patients, the following parameters were determined: serum creatinine content with the calculation of GFR using the CKD-EPI equation, potassium, sodium, phosphorus, free and ionized calcium, uric acid, glucose, aspartate aminotransferase, alanine aminotransferase, lipid spectrum, as well as the level of 24-hour MAU. The serum level of FGF23 was determined by enzyme immunoassay using the Human FGF-23 ELISA Kit. The measurement range was 0,1-20 pmol/l, sensitivity — 0,08 pmol/l.

We performed twenty four-hour ambulatory BP monitoring (ABPM) using the Schiller BR-102 plus system (Sweden) according to the generally accepted standard method, as well as echocardiography (Toshiba500, Japan) in 3 main modes. LV diastolic function was determined by the parameters of transmitral blood flow: peak early left ventricular filling (peak E), peak late left ventricular filling (peak A) and their ratio. LV mass (LVM) was determined by the formula of the American Society of Echocardiography (ASE), LVM index (LVMI). LVH was diagnosed with LVMI >115 g/m^2 in men and >95 g/m^2 in women [18]. LV relative wall thickness (RWT) was calculated as the ratio of the sum of interventricular septum and LV posterior wall thick-

Table 3

ABPM data (Me [25%; 75%])

Parameters	Controlled HTN (n=44)	Uncontrolled HTN (n=48)	p
SBP, mm Hg	127,0 [123,0; 129,0]	141,0 [137,0; 144,0]	<0,0001
DBP, mm Hg	77,0 [74,0; 80,0]	81,0 [77,0; 84,0]	0,043
Heart rate	74,0 [71,0; 80,0]	75,0 [71,0; 82,0]	0,572
PP	48,0 [46,0; 52,0]	59,0 [51,0; 65,0]	<0,0001
SBP load, day, %	21,0 [17,0; 26,0]	48,0 [36,0; 59,0]	<0,0001
DBP load, day, %	14,0 [8,0; 19,0]	35,0 [27,0; 59,0]	<0,0001
SBP load, night, %	20,0 [15,0; 29,0]	56,0 [44,0; 66,0]	<0,0001
DBP load, night, %	13,0 [4,0; 30,0]	40,0 [18,0; 60,0]	<0,0001
MBPS	15,0 [12,0; 18,0]	23,0 [20,0; 27,0]	<0,0001
Rate of MBPS	15,0 [11,0; 22,0]	27,0 [25,0; 29,0]	<0,0001
24-hour SBP index, %	9,0 [7,0; 12,0]	7,0 [3,0; 10,0]	0,020
24-hour DBP index, %	11,0 [6,0; 12,0]	8,0 [6,0; 15,0]	0,624

Abbreviations: HTN — hypertension, MBPS — morning blood pressure surge, DBP — diastolic blood pressure, PP — pulse pressure, SBP — systolic blood pressure.

Table 4

Laboratory data of patients with resistant hypertension (Me [25%; 75%])

Parameters	Controlled HTN (n=44)	Uncontrolled HTN (n=48)	p
GFR according to the CKD-EPI equation, ml/min/1,73 m²	82,0 [74,0; 87,0]	80,0 [71,0; 86,0]	0,112
Glucose, mmol/l	4,9 [4,5; 5,5]	5,0 [4,5; 5,6]	0,217
UA, µmol/l	345,0 [293,0; 387,0]	345,0 [312,0; 383,0]	0,737
MAU, mg/ml	9,0 [6,8; 10,7]	10,0 [6,9; 11,5]	0,238
Total cholesterol, mmol/l	5,8 [4,8; 6,4]	5,9 [4,8; 6,6]	0,522
LDL, mmol/l	4,0 [3,7; 4,3]	4,0 [3,8; 4,3]	0,562
HDL, mmol/l	1,2 [1,0; 1,4]	1,2 [0,9; 1,4]	0,315
TG, mmol/l	1,4 [1,2; 1,7]	1,5 [1,2; 1,8]	0,651
Total calcium, mmol/l	1,2 [1,1; 1,2]	1,1 [1,1; 1,2]	0,121
Ionized calcium, mmol/l	2,1 [2,1; 2,2]	2,2 [2,1; 2,2]	0,416
Phosphorus inorganic, mmol/l	1,6 [1,2; 2,1]	1,5 [1,2; 1,7]	0,156
Potassium, mmol/l	4,1 [3,7; 4,6]	4,1 [3,7; 4,5]	0,321
FGF23, pmol/ml	9,2 [7,1; 11,6]	11,7 [8,5; 15,4]	0,0036

Abbreviations: HTN — hypertension, HDL — high-density lipoprotein, LDL — low-density lipoprotein, MAU — microalbuminuria, UA — uric acid, GFR — glomerular filtration rate, TG — triglycerides, FGF23 — fibroblast growth factor-23.

ness to LV end-diastolic dimension. The type of LV geometry was determined according to the classification of A. Ganau (1992): normal LV geometry with LVMI <125 g/m² and RWT <0,42; concentric LV remodeling with LVMI <125 g/m² and RWT >0,42; concentric LVH with LVMI >125 g/m² and RWT >0,42; eccentric LVH with LVMI >125 g/m² and RWT <0,42.

Statistical analysis. Statistical processing was carried out using the statistical software package Statistica, v.12.0 (StatSoft, USA). The distribution of the studied parameters was carried out using the Kolmogorov-Smirnov test. Qualitative variables are presented as relative frequencies (n, %). Quantitative characteristics are presented as the interquartile interval median, Me [25%; 75%]. To confirm statistical significance, the Mann-Whitney U-test was used when comparing 2 independent groups. Spearman's rank correlation coefficient was used to assess the relationship between the considered features. Data differences and correlations between data were considered significant at p<0,05.

Table 5

Echocardiographic data of patients with resistant hypertension (Me [25%; 75%])

Parameters	Controlled HTN (n=44)	Uncontrolled HTN (n=48)	p
LA size, cm	41,0 [38,0; 42,0]	42,0 [39,0; 44,0]	0,054
EDD, cm	4,9 [4,7; 5,2]	5,0 [4,8; 5,2]	0,262
EDV, ml	105,0 [96,01; 113,0]	106,0 [93,0; 117,0]	0,318
ESD, cm	3,1 [2,8; 3,2]	3,1 [2,8; 3,3]	0,177
ESV, ml	38,0 [27,0; 44,0]	40,0 [29,0; 44,0]	0,225
SV, ml	69,0 [60,0; 76,0]	69,0 [58,0; 77,0]	0,432
IVST, cm	1,2 [1,1; 1,3]	1,3 [1,2; 1,4]	0,0043
LV PWT, cm	1,1 [1,0; 1,2]	1,1 [1,0; 1,3]	0,135
LV RWT	0,45 [0,43; 0,50]	0,50 [0,48; 0,53]	<0,0001
LVM, g	219,0 [168,0; 251,0]	226,0 [180,0; 276,0]	0,213
LVMI, g/m²	133,0 [115,0; 145,0]	134,0 [121,0; 150,0]	0,591
EF, %	60,0 [55,0; 67,0]	59,0 [54,0; 65,0]	0,682
E/A	0,9 [0,8; 1,0]	0,9 [0,8; 0,9]	0,298

Abbreviations: HTN — hypertension, LVMI — left ventricular mass index, EDD — end-diastolic dimension, EDV — end-diastolic volume, ESD — end-systolic dimension, ESV — end-systolic volume, LV — left ventricle, LA — left atrium, LVM — left ventricular mass, RWT — relative wall thickness, PWT — posterior wall thickness, IVST — interventricular septal thickness, SV — stroke volume, EF — ejection fraction.


Figure 1. Types of LV geometry in patients with resistant hypertension.
Abbreviations: CLVH — concentric left ventricular hypertrophy, CLVR — concentric left ventricular remodeling, LVH — normal left ventricular geometry, ELVH — eccentric left ventricular hypertrophy.

Results

According to the ABPM, patients were divided into following groups: 1 — controlled (n=44) and 2 — uncontrolled (n=48) resistant HTN. The clinical and demographic characteristics of the patients are presented in Table 1. The groups were comparable in terms of cardiovascular risk factors. Assessment of target organ damage (Table 2) (decrease in renal function, LVMI, and intima-media thickness) also did not reveal differences between the groups.

With a comparable duration of HTN, we found a longer history of regular antihypertensive therapy in the group of controlled resistant HTN (7,0 [4,0; 8,0] years in group 1 and 5,0 [4,0; 7,0] years in group 2, p=0,034). At entry into the study, 100% of participants received combined antihypertensive therapy with RAAS inhibitors, diuretics, calcium channel blockers, and an aldosterone receptor antagonist. In addition, 20,5% of patients in group 1 and 25% in group 2 took β-blockers, while 22,7% and 27,1% of patients in groups 1 and 2, respectively, took an imidazoline receptor agonist. The average number of drugs in group 1 was 4,4 [4,0; 4,6], in group 2 — 4,4 [4,1; 4,6] (p=0,673). Thus, the groups were comparable in qualitative and quantitative composition of therapy, which makes it possible to exclude a direct drug effect on the studied parameters.

The study design involved the division of patients with resistant HTN into groups depending on the achievement of the target BP level according to ABPM results against the background of comparable multicomponent therapy. In the group of uncontrolled resistant HTN, the main parameters of ABPM were higher (Table 3). The heart rate and 24-hour diastolic BP index were comparable [19-23].

There was no significant difference between the groups (Table 4) in standard laboratory investigations, including the level of GFR, MAU, uric acid, microelements and lipid profile, despite the fact that before inclusion in the study, none of the patients had received statin therapy for 6 months. In the

group of uncontrolled resistant HTN, the level of FGF23 was significantly higher — 11,7 [8,5; 15,4] pmol/ml vs 9,2 [7,1; 11,6] pmol/ml in group 1 (p=0,0036).

The echocardiographic data are presented in Table 5. The mean values of end-diastolic dimension, end-systolic dimension, end-systolic volume, end-diastolic volume, ejection fraction were within the normal range and did not differ in both groups of patients with resistant HTN. A comparable moderate increase in left atrial size and LV diastolic function impairment were found in the study of transmitral blood flow, regardless of the achievement of the target BP level. Also in both studied groups, a thickening of LV posterior wall and interventricular septum was revealed. At the same time, the greatest interventricular septum thickness values were found in patients of the 2nd group as follows: 1,3 [1,2; 1,4] cm vs 1,2 [1,1; 1,3] cm in group 1 (p=0,0043). But more significant differences were obtained when calculating the LV RWT: in group 1, LV RWT was 0,45 [0,43; 0,50], in group 2 — 0,50 [0,48; 0,53], p<0,0001. At the same time, LVM and LVMI were comparable.

When studying the type of LV geometry (Figure 1), we found that the leading patterns in groups 1 and 2 were concentric LVH — in 18 patients of group 1 and 26 in group 2 (p=0,044), less often — eccentric LVH. Thus, in the majority of patients with resistant HTN, we found a change in LV shape from physiological ellipsoid to hemodynamically unfavorable spherical, thickening of LV walls with a regular increase in myocardial mass and the formation of predominantly hypertrophic LV remodeling.

To assess the relationship between the studied parameters, we conducted a correlation analysis, which found a positive relationship of pulse pressure (PP) with HTN duration (r=48, p=0,02) and FGF23 level (r=0,62, p=0,004). LVMI was positively associated with the time index for diastolic BP (r=51, p=0,02). A positive correlation was also found between LV RWT and PP (r=0,64, p=0,02) and a negative relationship with the duration of regular antihypertensive therapy (r=47, p=0,04). But the strongest relationship was found between LV RWT and FGF23 levels (r=0,75, p=0,005).

Discussion

The risk of LVH in patients with resistant HTN is significantly higher than in the general population of patients with HTN (odds ratio, 2,1, confidence interval, 1,2-3,6) [24]. As is known, LVH is a modifiable risk factor, and a decrease in LVM, in addition to a decrease in BP, is one of the essential criteria for the effectiveness of antihypertensive therapy. It is known that an intensive decrease in BP is accom-

panied by a more pronounced regression of LVH [25]. In the present study, patients with resistant HTN had elevated LVM and LVMI, regardless of the achievement of the target BP level. These results can be explained by the fact that long-term use of RAAS blockers and calcium channel antagonists leads to LVH regression, regardless of the achievement of the target BP level [17]. At the same time, we found significantly higher RWT values and more frequent development of the concentric LVH variant in patients with uncontrolled resistant HTN.

We also found higher PP values in patients with uncontrolled resistant HTN. This is consistent with the results of the Swedish Primary Care Cardiovascular Database (SPCCD) cohort study [26], in which a pattern of isolated systolic hypertension (ISH) was more frequently detected in patients with uncontrolled resistant HTN. It is known that ISH is currently considered as the main risk factor for CVEs in the elderly. The results of numerous studies have shown that the development of LVH and LV remodeling in ISH is associated not only with the level of systolic BP, but also with PP and the related vascular stiffness, which in this study is confirmed by the presence of a relationship between LV RWT and PP.

As already mentioned, FGF23 is a direct mediator of LVH development [10-12]. It was found that in patients with resistant HTN, LVM and LVMI were significantly higher with a higher level of FGF23 [17]. In this study, the level of FGF23 was higher in patients with uncontrolled resistant HTN, but we did not find an association with LVM. At the same time, FGF23 was associated with the PP value according to ABPM and LV RWT. The revealed relationships can be explained by the fact that FGF23 is one of the humoral regulators of vascular calcification [9]. In HTN, the level of FGF23 correlates with aortic calcification, which is known to make a significant contribution to the progression of vascular stiffness, an increase in heart afterload, and the development of LVH [24]. Increased vascular stiffness is a strong independent predictor of all CVEs in all categories of patients with cardiovascular pathology, and the most pronounced vascular changes were found in patients with resistant HTN, even when target BP was achieved against the background of antihypertensive therapy [24].

Study limitations. This cross-sectional single-center study was performed in a selected cohort of patients with resistant HTN without associated clinical conditions and clinically significant comorbidities, who received proper antihypertensive therapy and were regularly observed by specialists. In this regard, the features of myocardial remodeling identified and their relationship with the FGF23 level can-

not reflect the structural and geometric myocardial changes in the general population of patients with resistant HTN. To evaluate the studied parameters in patients with resistant HTN, large multicenter studies are required.

Conclusion

For patients with uncontrolled resistant HTN, an increase in PP and myocardial remodeling in the form of concentric hypertrophy are more characteristic. FGF23 is significantly higher in uncontrolled resistant HTN and is positively associated with PP and RWT. Although these results need to be confirmed in a larger prospective study, these data suggest that FGF23 may play an important role in LV remodeling in patients with resistant HTN.

Relationships and Activities: none.

References

1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010.
2. Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.
3. Cao G, Chen C, Lin Q, et al. Prevalence, clinical characteristics and echocardiography parameters of non-resistant, resistant and refractory hypertension in Chinese. Postgrad Med. 2017;129(2):187-92. doi:10.1080/00325481.2017.1272398.
4. Cuspidi C, Vaccarella A, Negri F, Sala C. Resistant hypertension and left ventricular hypertrophy: an overview. J Am SocHypertens. 2010;4(6):319-24. doi:10.1016/j.jash.2010.10.003.
5. Cuspidi C, Sala C, Negri F, et al. Italian Society of Hypertension. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012;26(6):343-9. doi:10.1038/jhh.2011.104.
6. Pedersen LR, Kristensen AMD, Petersen SS, et al. Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography. J Clin Hypertens (Greenwich). 2020;22(9):1647-58. doi:10.1111/jch.13991.
7. Alsharari R, Oxborough D, Lip GYH, Shantsila A. Myocardial Strain Imaging in Resistant Hypertension. Curr Hypertens Rep. 2021;23(5):24. doi:10.1007/s11906-021-01148-3.
8. Koziolova NA, Shatunova IM, Lazarev IA. Incidence and features of left ventricular hypertrophy in highly compliant hypertensive patients. "Arterial'naya Gipertenziya" ("Arterial Hypertension"). 2011; 17(5):454-9. (In Russ.) doi:10.18705/1607-419X-2011-17-5-454-459.
9. Mace ML, Olgaard K, Lewin E. New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis. Int J Mol Sci. 2020;21(22):8810. doi:10.3390/ijms21228810.
10. Chua W, Purmah Y, Cardoso VR, et al. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. Eur Heart J. 2019;40:1268-76. doi:10.1093/eurheartj/ehy815.
11. Navarro-García JA, Fernández-Velasco M, Delgado C, et al. PTH, vitamin D, and the FGF-23-klotho axis and heart: Going beyond the confines of nephrology. Eur J Clin Invest. 2018;48(4). doi:10.1111/eci.12902.
12. Fujii H, Watanabe K, Kono K, et al. Changes in serum and intracardiac fibroblast growth factor 23 during the progression of left ventricular hypertrophy in hypertensive model rats. Clin Exp Nephrol. 2019;23(5):589-96. doi:10.1007/s10157-018-1680-1.
13. Grabner A, Schramm K, Silswal N, et al. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Sci Rep. 2017;7:1993. doi:10.1038/s41598-017-02068-6.
14. Leifheit-Nestler M, Kirchhoff F, Nespor J, et al. Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts. Nephrol Dial Transplant. 2018;33(10):1722-34. doi:10.1093/ndt/gfy006.
15. Böckmann I, Lischka J, Richter B, et al. FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis. Int J Mol Sci. 2019;20(18):4634. doi:10.3390/ijms20184634.
16. Neuburg S, Dussold C, Gerber C, et al. Genetic background influences cardiac phenotype in murine chronic kidney disease. Nephrol Dial Transplant. 2018;33(7):1129-37. doi:10.1093/ndt/gfx332.
17. Chen JS, Pei Y, Li CE, et al. Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: A network meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich). 2020;22(12):2175-83. doi:10.1111/jch.14047.
18. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70. doi:10.1093/ehjci/jev014.
19. Gorbunov VM. Ambulatory blood pressure monitoring: modern aspects. Moscow: Logosphere, 2015 p. 240. (In Russ.) ISBN: 978-5-98657-051-8.
20. Larina VN, Fedorova EV, Kulbachinskaya OM. Morning blood pressure: review of national and foreign literature. "Lechebnoyedelo" ("Medical business"). 2019;3:66-73. (In Russ.) doi:10.24411/2071-5315-2019-12143.
21. Polonsky TS, Bakris GL. Ambulatory Blood Pressure Monitoring. JAMA. 2018;320(17):1807-8. doi:10.1001/jama.2018.14856.
22. Kario K. Nocturnal Hypertension: New Technology and Evidence. Hypertension. 2018;71(6):997-1009. doi:10.1161/HYPERTENSIONAHA.118.10971.
23. Sogunuru GP, Kario K, Shin J, et al. HOPE Asia Network. Morning surge in blood pressure and blood pressure variability in Asia: Evidence and statement from the HOPE Asia Network. J Clin Hypertens (Greenwich). 2019;21(2):324-34. doi:10.1111/jch.13451.
24. Cardoso CRL, Salles GF. Associations of the nocturnal blood pressure fall and morning surge with cardiovascular events and mortality in individuals with resistant hypertension. J Hypertens. 2021;39(6):1177-87. doi:10.1097/HJH.0000000000002775.
25. Bourdillon MT, Vasan RS. A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy. Curr Hypertens Rep. 2020;22(10):85. doi:10.1007/s11906-020-01092-8.
26. Holmqvist L, Boström KB, Kahan T, et al. Cardiovascular outcome in treatment-resistant hypertension: results from the Swedish Primary Care Cardiovascular Database (SPCCD). J Hypertens. 2018;36(2):402-9. doi:10.1097/HJH.0000000000001561.